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Abstract The final step in the biosynthesis of nicotinamide-
adenine dinucleotide, a major coenzyme in cellular redox
reactions and involved in intracellular signaling, is catalyzed by
the enzyme nicotinamide mononucleotide adenylyltransferase
(NMNAT). The X-ray structure of human NMNAT in complex
with nicotinamide mononucleotide was solved by the single-
wavelength anomalous dispersion method at a resolution of 2.9
Aî . Human NMNAT is a symmetric hexamer whose subunit is
formed by a large six-stranded parallel L-sheet with helices on
both sides. Human NMNAT displays a different oligomerization
compared to the archaeal enzyme. The protein^nicotinamide
mononucleotide interaction pattern provides insight into ligand
binding in the human enzyme. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Nicotinamide-adenine dinucleotide (NAD) is an essential
molecule in all cells as coenzyme of oxidoreductases. It also
is an important constituent of several intracellular signaling
pathways [1]. The ¢nal step in the biosynthesis of NAD,
the transfer of the adenylyl moiety of ATP to nicotinamide
mononucleotide (NMN), is catalyzed by nicotinamide
mononucleotide adenylyltransferase (NMNAT; E.C. 2.7.7.1)
[2] :
NMNATP! NAD  PPi
Human NMNAT is a 32-kDa protein that has been puri¢ed
from placenta [3] and as recombinant protein [4,5]. It is easily
assayed by monitoring the reduction of NAD by alcohol
dehydrogenase [6].
NMNAT is thought to play an important role in regulating
the cellular NAD pool after episodes of increased DNA
damage, since it has been described to be associated with
poly(ADP-ribosyl) polymerase (PARP1) [7,8]. Among numer-
ous other processes, PARP1 is part of the DNA base-excision
repair system [9^11] and therefore may consume a consider-
able amount of cellular NAD under conditions of genotoxic
stress. NMNAT is down-regulated in tumor cells and has
been proposed as a chemotherapeutical drug target for this
reason [12^15].
Three structures of two archaeal NMNATs have been pub-
lished, one from Methanococcus jannaschii, PDB code 1f9a, in
complex with ATP [16] and two from Methanobacterium ther-
moautotrophicum, PDB codes 1ej2 and 1hyb, in complex with
NAD and NMN/SO234 , respectively [17,18]. Both enzymes
share extensive sequence (55%) and structural similarity
(root-mean-square deviation (r.m.s.d.) 1.02 Aî , calculated
with Swiss PDB Viewer [19]). Apparently, ligand binding
has no substantial e¡ect on the overall protein conformation.
However, sequence similarity to the human protein is very
low: 15.5% (M. jannaschii) and 15.4% (M. thermoautotrophi-
cum) [20] ; all sequence identities calculated with the program
ALIGN (GeneStream Server).
Recently published were a number of additional structures
of nicotinamide/nicotinate mononucleotide adenylyltransfer-
ases, which are: human NMNAT apoenzyme, PDB code
1kku [21] ; human NMNAT in complex with deamido-nico-
tinamide-adenine dinucleotide (NaAD), NAD and L-CH2^tia-
zofurin adenine dinucleotide, PDB codes 1kqo, 1kqn and
1kr2, respectively [22] ; Escherichia coli NaMNAT apoenzyme
and complex with NaAD, PDB codes 1k4k and 1k4m, respec-
tively [23] ; Bacillus subtilis NaMNAT apoenzyme and com-
plex with NaAD, PDB codes 1kam and 1kaq, respectively
[24].
NMNAT is a member of the nucleotidyltransferase super-
family of K/L phosphodiesterases, proposed by Izard and
Geerlof [25]. The related SCOP superfamily is the nucleotidyl-
yltransferase superfamily [26]. Members include class I amino-
acyl-tRNA synthetases (catalytic domain) [27], cytidyltransfer-
ase [28], ATP sulfurylase [29,30], and phosphopantetheine
adenylyltransferase (PPAT) [25].
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2. Materials and methods
2.1. Expression, puri¢cation, crystallization, X-ray di¡raction and data
reduction
Expression of the human NMNAT cDNA in E. coli [4], puri¢cation
of the protein and crystallization was performed as previously de-
scribed [20]. The growth medium and conditions were modi¢ed ac-
cording to a protocol of Van Duyne et al. [31] to produce protein that
contains selenomethionine (SeMet) in place of methionine. A com-
plete dataset at wavelength 0.9795 Aî (peak of the £uorescence spec-
trum) was collected at beamline ID14-4, ESRF Grenoble, with re£ec-
tions at a maximum resolution of 2.7 Aî . Data were processed using
DENZO and SCALEPACK [32].
2.2. Phase determination and re¢nement
Phases were determined with SOLVE [33] using only the peak data-
set (maximal resolution used: 3.7 Aî ) and, therefore, the single-wave-
length anomalous dispersion (SAD) method. Phases were improved
by maximum-likelihood density modi¢cation, using RESOLVE [34] as
well as non-crystallographic symmetry (NCS) averaging. For the lat-
ter, the three-fold NCS observed in the electron density was used in
DM [35]. This program was also used for phase extension to 2.9 Aî .
The protein model was built by ¢rst placing a poly-alanine trace into
the electron density of the peptide backbone and then mutating the
residues according to the sequence of NMNAT (program ONO [36]).
With the best selenium coordinates obtained this way, the phases were
improved by re-running SOLVE, now omitting the NCS averaging by
DM and using re£ections up to 2.9 Aî resolution, making phase ex-
tension by DM unnecessary. For re¢nement, the maximum-likelihood
method as well as one simulated annealing step were used (programs
REFMAC5 [35] and CNS [37], respectively). NCS restraints as well as
B-factor restraints were held tight for the backbone and relaxed for
the side-chain atoms during re¢nement.
3. Results and discussion
3.1. Puri¢cation, crystallization and structure determination
To produce SeMet-substituted NMNAT, recombinant
E. coli cells were grown in a medium depleted of methionine,
to which SeMet was added prior to induction. This way, Se-
Met was incorporated into NMNAT quantitatively. SeMet
was detected by mass spectrometry. For example, the frag-
ment Val67^Lys75 contained almost exclusively SeMet. SeMet
substitution was also con¢rmed by a £uorescence scan prior
to the di¡raction experiment (data not shown). The crystalli-
zation conditions have been described elsewhere [20]. The en-
zyme activity remained una¡ected by incorporating SeMet
and was as previously described [4].
Phases yielding readily interpretable electron density were
calculated with the SAD method. The number of nine sites in
the Patterson map immediately indicated a three-fold symme-
try of NMNAT which contains three internal methionines per
subunit plus the N-terminal Met later found to be disordered.
A trimer representing the asymmetric unit of the crystal was
indeed seen in the electron density and used for NCS averag-
ing. Despite this, the single monomers show some £exibility
with respect to each other. The r.m.s.d. (calculated with the
program LSQKAB [35]) between the monomers is 0.125/0.777
Aî (main chain/all atoms) for monomers A and B, 0.131/0.850
Aî for A and C, and 0.125/0.689 Aî for B and C. The rotation
angles are 119.16‡ between monomers A and B, 121.23‡ be-
Table 1
Data-collection and re¢nement statistics
Data collection
Wavelength (Aî ) 0.9795
Resolution (Aî ) 20^2.9 (3.0^2.9)
No. of observations 632 186
Unique re£ections 62 691 (5937)
Data completeness (%) 98.3 (92.5)
Average I/c(I) 11.2 (1.1)
Ramerge (%) 7.0 (49.2)
Space group C2221
Unit cell parameters (Aî ) a = 140.8; b = 235.7;
c = 89.0
Monomers in the asymmetric unit 3
Re¢nement
Structure determination method SAD
Se sites per asymmetric unit (no.) 9
Protein atoms (non-hydrogens) (no.) 5481
NMN atoms (non-hydrogens) (no.) 66
Rbcryst (%) 25.3
Rcfree (%) 29.1
r.m.s.d. bond lengths (Aî ) 0.018
r.m.s.d. bond angles (degrees) 1.719
Average B-factord, all atoms (Aî 2) 52.0
Average r.m.s.d. for mainchain B-factorsd (Aî ) 1.35
Average r.m.s.d. for sidechain B-factorsd (Aî ) 4.03
Values in parentheses refer to the outer resolution shell.
aRmerge =4hkl 4iMIi3GIfM/4GIf where Ii is the intensity of the observa-
tion of re£ection hkl, and GIf is the average intensity of this re£ec-
tion.
bRcryst =4MFobs3FcalcM/4MFobsM.
cRfree was calculated using 7% randomly selected re£ections.
dCalculated with BAVERAGE [35].
Fig. 1. Ribbon model (a) and topology diagram (b) of human
NMNAT (PDB code 1gry) in complex with NMN. Strands are in
yellow/orange, helices in light and dark blue; atom colors: C, gray;
N, blue, O, red; P, green.
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tween A and C, yielding a slightly improper three-fold non-
crystallographic axis. A crystallographic two-fold axis forms a
hexamer with 32 point symmetry as biological unit. The elec-
tron density of the hexamer is clearly separated from solvent
in the unit cell, and subunit contacts in the hexamer are much
tighter than typical lattice contacts. In principle, but not in
detail (see below), the quaternary structure of human
NMNAT resembles that of two archaeal NMNATs [16,18].
Data collection and re¢nement statistics are given in Table 1.
3.2. Overall structure and oligomerization
The limited resolution of 2.9 Aî , the relatively poor signal-
to-noise in the high-resolution bins (re£ections from 2.9 to 2.7
Aî were not used) and the high average B-factor of the dif-
fraction data permit a clear view of the global structure, but
make it di⁄cult to discuss ¢ne structural details. The overall
fold, the backbone and most side chains are well de¢ned as
well as a part of the ligand. Not seen in the electron density is
a loop ranging from residues Leu106 to Lys146 as well as part
of the ligand (see below). The missing loop, that is disordered
in all three human structures (1KKU: residues 111^147 [21] ;
1KYN: residues 109^146 [22]), contains a nuclear localization
sequence, residues Pro123 to Trp129 [4] and is located at the
outside of the biological hexamer (see Fig. 4a). Obviously, this
part of the enzyme is highly £exible and accessible as indi-
cated by the ¢nding that trypsin cleaves human NMNAT
preferentially at position Lys146 (data not shown).
The structure of human NMNAT consists of a large six-
stranded parallel L-sheet that accounts for 16% of the se-
quence. On both sides, the sheet is covered by helices (40%
of the structure), see Fig. 1 for a ribbon model of the (KL-)
structure (a) and a topology diagram (b). Overall conforma-
tional di¡erences of the three human NMNAT structures are
not obvious as judged from the published ribbon representa-
tions (coordinates are not available yet). For E. coli, NMNAT
drastical conformational changes upon ligand binding were
reported [23]. Structure and sequence of NMNAT from
M. thermoautotrophicum (PDB codes 1ej2 (with NAD) and
1hyb (with NMN) [18]) and M. jannaschii (PDB code 1f9a
(with ATP) [16] are very similar with respect to each other.
Both do not show signi¢cant sequence similarity to the human
enzyme: 15.5% identity to M. jannaschii NMNAT and 15.4%
to M. thermoautotrophicum NMNAT after ClustalW align-
ment [20]). However, the structures share a common core.
Compared to M. thermoautotrophicum NMNAT, the human
enzyme contains approximately 50% more residues which ac-
count for additional secondary structure elements, highlighted
in darker colors in Fig. 1a (dark blue for helices E, G and H;
orange for strand f), and the missing loop from Leu106 to
Lys146. See Fig. 2 for a structural alignment of the backbone
of human and archaeal NMNATs. The CK chains of the
human and either one of the archaeal structures can be super-
imposed with an r.m.s.d. of 1.62 Aî (calculated with Swiss
PDB Viewer [19]).
Fig. 3 shows a sequence alignment, optimal with respect to
the scoring function (sum-of-pairs alignment calculated with
Fig. 2. Alignment of backbone atoms of human NMNAT (1gry, chain A, with NMN; red), M. thermoautotrophicum NMNAT (1ej2, with
NAD ; dark blue and 1hyb, with NMN; light blue) and M. jannaschii NMNAT (1f9a, chain A, with ATP; green). All proteins were aligned
with 1ej2 as rigid chains. Helices E, F, G and H of 1gry, which are di¡erent or additional with respect to the archaeal enzymes, are shown
with increased chain diameter.
Fig. 3. Sequence alignment and associated secondary structure of
human (Hsa) and M. thermoautotrophicum (Mth; numbering ac-
cording to the original publication) NMNAT. Ligand-binding resi-
dues are highlighted in black boxes, the conserved residues of the
conserved motifs GXXXPX(H/T)XXH and SXTXXR are framed;
color code as in Fig. 1.
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MSA [38]) of human and M. thermoautotrophicum NMNAT.
Although the sequence similarity is weak, many secondary
structure elements in fact do align. Helix F, which harbors
or is near several of the ligand-binding residues is aligned with
helix K3 of the archaeal NMNAT. However, a 3D-structure
comparison (Fig. 2) shows that helix D of the human enzyme
is the equivalent to this helix K3. This and the fact that NMN
in the human enzyme is twisted compared to the ligand in the
archaeal protein (see Figs. 2 and 5c) is a clear indication of a
di¡erent cofactor binding behavior. Helix F, which together
with helix E replaces M. thermoautotrophicum helix K4, is on
the other side of that fork-like ligand-binding structural ele-
ment.
The additional residues are also responsible for clear di¡er-
ences in the oligomerization of human NMNAT compared to
the archaeal proteins (here shown and discussed for the
M. thermoautotrophicum NMNAT [18]). This is hardly re-
£ected in accessible surface area buried in the subunit inter-
face (Fig. 4b) which, surprisingly, is almost identical for both
proteins (approximately 2000 Aî 2 per subunit; calculated with
NACCESS [39], Fig. 4b). In the archaeal hexamer, the
L-strands point towards the center of the hexamer, and the
monomers sit squarely atop each other. In the human protein
the monomers are oriented di¡erently. The strands point more
sideways and the monomers have extensive overlap to the
adjacent monomers of the second-plane trimer (e.g. mono-
mers A and D). The strands L3 (corresponding to the human
strands d) of adjacent monomers A and E contact each other
and are parallel in archaeal NMNAT. In human NMNAT,
the opposite strands f (that have no correspondence in the
archaeal proteins) do not contact directly, are antiparallel
and formed by di¡erent monomers (A and D).
Fig. 4c shows details of the protein^protein interface in the
human hexamer. Hydrogen bonds and hydrophobic contacts
form a widespread net of interactions. In human NMNAT the
dyad axis promotes interactions between helix A (residues 26^
33; monomer A) and loop I^J (residues 234^237; monomer
E) as well as, vice versa, loop I^J of monomer A and helix A
of monomer E. Besides this, residues of monomer A contact
those of monomer D. For example, a hydrogen bond between
GlyA37 and ArgD207 is formed and a stacking of the aro-
matic rings of TyrA198 and TrpD216 is established. These
contacts are repeated between momers B and D/F and be-
tween C and F/E. Within monomers related by the triad
axis, residues 198^201 (helix G, monomer A) contact residues
228^232 (strand I, monomer B), which is regularly repeated
between monomers B and C, C and A, D and E, E and F,
and F and D. Most prominent are hydrogen bonds between
Tyr198 and Arg232 and between Asp201 and Arg231, as well
as a hydrophobic interaction between ArgA207, TrpA204 and
ArgB232.
Triad axis interactions in the archaeal NMNAT are formed
between helix K4 (corresponding to human helix F) of mono-
mer A and helix K7 (corresponding to human loop J^K) of
monomer B. This interaction is no longer possible in the hu-
man protein, because the additional helices G and H, lying
right between them, drastically increase the distance between
respective structural elements. Due to this changed overlap of
adjacent trimer subunits, the lower trimer is forced to rotate
with respect to the upper trimer where all monomers them-
selves are rotated compared to the archaeal hexamer arrange-
ment.
Fig. 4. Protein^protein interactions. a: Top view of the hexamer of
human NMNAT with each subunit in a separate color (chain ID
near the N-termini). Monomers A, B and C form the upper trimer,
monomers D, E and F the lower trimer. b: Side view of human
and M. thermoautotrophicum NMNAT in space-¢lling representa-
tion. Numbers represent the accessible surface area in Aî 2 of subunit
A buried in the subunit interface by the adjacent subunits. No con-
tact is formed between monomers A and F in the human NMNAT
or between A and D in the archaeal NMNAT. c: Contact area of
human monomer A with its adjacent subunits B, D and E. Color
code as in (b). Selected hydrogen bonds are shown as dotted lines,
the label-color re£ects the harvesting subunit. Subunits B, C and F
are not shown.
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The oligomerization of human NMNAT described here is
in general consistent with the results of Garavaglia et al. [21]
and Zhou et al. [22], although slight di¡erences are reported
(e.g. di¡erent hydrogen bonds for Tyr198). Since the structure
described here has a leucine at position 217 (1KKU: Phe; a
single nucleotide polymorphism [4]), the contact between re-
gions 217^220 (loop f^I; monomer A) with the same region of
monomer E is less intimate.
Bacterial NMNAT, in contrast to the hexameric archaeal
and human proteins, is reported to occur in monomeric
(E. coli [23]) or dimeric (B. subtilis [24]) forms.
3.3. Ligand binding
The crystallization bu¡er contained the cofactor NAD at
1 mM concentration (1.6-fold molar excess with respect to the
protein). In the electron density, only the NMN moiety of the
ligand is seen. Although it cannot be excluded that the enzyme
hydrolyzed NAD, it is more likely that the AMP or the
adenosine part of NAD is not revealed by the electron den-
sity due to positional £exibility. In fact, di¡erence density is
observed at a position where the second phosphate or the
AMP ribose could be placed (Fig. 5b), close to His24, a po-
tential ligand-binding residue and member of the highly con-
served GXXXPX(T/H)XHXXH motif in all NMNAT se-
quences (see Fig. 3 and ref. [22]). B-factors of the ligand
atoms are similar to those of nearby protein atoms, but
slightly increased for the phosphate atoms, indicating a dis-
ordered adenylyl phosphate portion. An alternative possibility
is that NMN was trapped in the protein during cell growth, as
it was observed for the NMNAT structures of M. thermoau-
totrophicum [18]. However, since the AMP part is disordered
or not present, this structure has to be discussed as a
NMNAT^NMN complex.
The ligand-binding pocket faces the outer edges of the hex-
amer, being slightly tilted towards the central channel. The
C-terminus may serve as a ‘lock’ of the cavity. NMN binding
is achieved by hydrogen bonding and hydrophobic contacts of
several amino acids of the binding pocket (Fig. 4, left). Most
prominent are contacts of Ser16 and Lys57 with the phos-
phate oxygens and those of Glu94 to the nicotinamide and
the ribose oxygens, as well as the stacking of Trp169 (con-
served in all NMNAT sequences) with the nicotinamide. It
has to be mentioned that within the three monomers in the
asymmetric unit of the structure, the hydrogen bonding pat-
tern is not strictly conserved. This could re£ect £exibility of
the binding pocket. For example the amido-nitrogen (N7) of
NMN is hydrogen-bonded to the carbonyl oxygen of Leu168
(chain B) or to Asp173-OD1 (chain A). This binding-site £ex-
ibility is in line with the observation that NMNAT also cata-
lyzes the synthesis of nicotinic acid adenine dinucleotide
(NaAD) [40], see the discussion of NaAD binding to
NMNAT [22].
Taking into account the limited resolution of our analysis
and the observed binding-site £exibility, these results are in
general agreement with the ligand-binding residues proposed
for the NMNAT apoenzyme (1KKU) [21] and with the li-
gand-binding residues observed in the NMNAT^NAD com-
plex (1KQN) [22]. Two residues, however, are clearly di¡er-
ent. In the apoenzyme, Glu94 is oriented away from the
ligand-binding pocket whereas Trp92 is facing it. Here,
Glu94 binds the ligand and the sidechain of Trp92 points
away from the ligand (shortest distance of the ligand to
Trp92 is 4.4 Aî between the backbone carbonyl oxygen and
the ribose oxygen O2R). In the NMNAT^NAD complex,
both residues participate in ligand binding. One could spec-
ulate that binding of NMN to the pocket is facilitated by a
£ip of the Glu94 sidechain and that Trp92 is part of an open^
close system that is possibly connected to ATP binding.
Except for the stacking interaction of Trp169 (correspond-
Fig. 5. Ligand-binding site of NMNAT. a: Human NMNAT bind-
ing NMN (chain A). Hydrogen bonds between protein residues and
the ligand are shown as dotted lines, residue Trp169, stacking on
the pyrimidine ring of NMN, is shown in green. Color code as in
Fig. 1. b: Fo^Fc di¡erence electron density map of the ligand-bind-
ing site (chain A). Calculated after re¢nement of the ¢nal model
without the ligand, contoured with 2.5c. Ball and stick representa-
tions of the ligand and adjacent amino acid side chains are shown.
c: Ligand-binding site of human (1gry, chain A; amino acids in
red, NMN in yellow) and M. thermoautotrophicum NMNAT (1ej2,
amino acids in dark blue, NAD in light blue) after alignment of
the whole proteins. Hydrogen bonds between the protein residues
and the ligand are shown as dotted lines in the respective color
(1gry: red; 1ej2: blue).
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ing to Trp87 in M. thermoautotrophicum NMNAT) and the
possible hydrogen bonding of His24 (corresponding to
M. thermoautotrophicum His19), only Ser16 is a conserved
residue involved in ligand binding (see Figs. 3 and 5c). The
tryptophans even belong to di¡erent regions of the proteins
(loop E^F in human NMNAT, helix K3, corresponding to
human helix D, in M. thermoautotrophicum). NMN in the
human NMNAT structure presented here is rotated with re-
spect to NAD in M. thermoautotrophicum (Fig. 5c) and gen-
erally bound di¡erently. Nevertheless, the active site and the
ligand binding is to some extent similar in both structures of
NMNAT, especially for the AMP part of the ligand.
Although not matched by the sequence alignment, the
AMP-binding residues Tyr130, Phe125 and Gly104 of
M. thermoautotrophicum can be structurally related to human
Ile221, Asn219 and Gly156 respectively (Fig. 5c). This is also
true for PPAT for which a crystal structure in complex with
dephospho-CoA is available (PDB code 1b6t [25]). In fact,
PPAT gives the highest Z-score (13.8) in a DALI search
[41] (M. jannaschii NMNAT, PDB code 1f9a, in second place
with Z-score 11.6) and can be superimposed to the human
NMNAT with a lower r.m.s.d. (1.41 Aî ) than the archaeal
NMNATs.
4. Conclusion
The X-ray structure of the human NMNAT shows a glob-
ular (KL) fold. The peptide stretch Leu106^Lys146, that con-
tains the nuclear localization sequence and is not found in
archaeal NMNATs, is located at the surface of the biological
hexamer and not resolved in the structure due to disorder.
Compared to the structures of two archaeal NMNATs, the
human enzyme displays a di¡erent oligomerization, mediated
by extra secondary structure elements. Three structures of
human NMNAT, each recently published with a di¡erent li-
gand bound, reveal conformational di¡erences of residues
Glu94 and Trp92, that permit discussing a possible ligand-
binding mechanism. The structure may help understand the
role of human NMNAT in cellular signaling and permit to
exploit the protein as a chemotherapeutical drug target.
5. Accession number
Coordinates of the structure of human NMNAT in com-
plex with NMN have been deposited in the Protein Data
Bank [42], PDB code 1gry.
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